© 2023 BioMarin. All rights reserved.

Investors & Media
Stock Quote
Transforming Lives Through Genetic Discovery

We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.

Fast Facts

>$2 Billion

in 2022 FY Total Revenues

78 Countries

Commercial Footprint

World-class Capabilities

Manufacturing, R&D, Regulatory, and Commercial

"Core 4" Product Framework

Genetic, Targeted, Assessable, Transformational

Wednesday, May 10, 2023
3:40pm PDT
Wednesday, April 26, 2023
1:30pm - 2:30pm PDT

All Events

Latest News
May 4, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care...

Apr 26, 2023

Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed;...

Apr 13, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...

All Press Releases

Annual Meeting 2023

The 2023 Annual Meeting of Stockholders of BioMarin Pharmaceutical Inc. will be held on Tuesday, May 23, 2023 at 10:00 a.m. (Pacific Time).


Learn More

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.


Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.


Learn More


Our executive team is made up of tech leaders with diverse backgrounds and a singular focus.



Contact Us

Investor Relations

Media & Press

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more!